Edition:
United States

Celsion Corp (CLSN.O)

CLSN.O on Consolidated Issue listed on NASDAQ Capital Market

0.23USD
26 May 2017
Change (% chg)

$-0.01 (-3.69%)
Prev Close
$0.24
Open
$0.24
Day's High
$0.25
Day's Low
$0.22
Volume
892,806
Avg. Vol
2,242,810
52-wk High
$1.60
52-wk Low
$0.19

Latest Key Developments (Source: Significant Developments)

Celsion Corp announces stock consolidation
Friday, 26 May 2017 04:05pm EDT 

May 26 (Reuters) - Celsion Corp :Celsion Corp announces stock consolidation.Is effecting a 1 for 14 reverse stock split of its common stock.Reverse stock split of its common stock which will be effective for trading purposes as of commencement of trading on May 30, 2017.  Full Article

Celsion Corp reports Q1 loss share per $0.12
Friday, 12 May 2017 08:00am EDT 

May 12 (Reuters) - Celsion Corp -:Celsion Corporation reports first quarter 2017 financial results and provides business update.Q1 loss share per $0.12.Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.Celsion Corp - research and development costs were relatively constant at $3.5 million and $3.4 million in first quarters of 2017 and 2016, respectively.Celsion Corp - plans to activate 5 additional clinical trial sites in vietnam by q2 of 2017 for optima study.Celsion Corp - company ended q1 of 2017 with $4.5 million of total cash and cash equivalents.  Full Article

Celsion Corp files for stock shelf of up to $15 mln
Tuesday, 25 Apr 2017 05:12pm EDT 

April 25 (Reuters) - Celsion Corp :Celsion Corp files for stock shelf of up to $15 million - SEC filing.  Full Article

Celsion Corp says selling stockholders may offer up to 5.1 mln shares of common stock - SEC Filing
Wednesday, 5 Apr 2017 05:39pm EDT 

Celsion Corp :Celsion Corp - Selling stockholders may offer up to 5.1 million shares of common stock, issuable upon exercise of outstanding warrants - SEC Filing.  Full Article

Celsion presents two posters on its GEN-1 IL-12 gene-mediated immunotherapy
Monday, 27 Feb 2017 08:30am EST 

Celsion Corp : Celsion presents two posters on its GEN-1 IL-12 gene-mediated immunotherapy at the ASCO-SITC clinical immuno-oncology symposium . Celsion Corp - in first twelve patients dosed in ovation study, GEN-1 plus standard chemotherapy produced impressive clinical results . Celsion Corp - Celsion expects to complete enrollment and treatment phase of ovation study early in Q2 .Celsion - expects to report final data from ovation study , including translational data for all patients, by end of Q2 of 2017.  Full Article

Celsion files for offering of up to $15 mln in shares of common stock and base warrants
Friday, 23 Dec 2016 03:04pm EST 

Celsion Corp : Files for offering of up to $15 million in shares of common stock and base warrants - SEC filing .Says shares of its common stock and base warrants are immediately separable and will be issued separately, but will be purchased together in the offering.  Full Article

Celsion posts Q2 loss of $0.19/share
Monday, 15 Aug 2016 09:00am EDT 

Celsion Corp: Celsion Corporation reports second quarter 2016 financial results and provides business update . Q2 loss per share $0.19 .Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

Celsion Co, Zhejiang Hisun Pharma sign deal for development of GEN-1 immuno-oncology therapy
Tuesday, 9 Aug 2016 09:00am EDT 

Celsion Corp : Co, Zhejiang Hisun Pharma sign technology transfer, manufacturing and commercial supply deal for development of GEN-1 immuno-oncology therapy . Hisun will collaborate with Celsion around regulatory approval activities for GEN-1 with CFDA . Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with company's current suppliers .Will provide Hisun a percentage certain of China's commercial unit demand, and separately of global commercial unit demand.  Full Article

Celsion expects to report translational data from first two cohorts of ovation study in Q3
Tuesday, 24 May 2016 08:00am EDT 

Celsion Corp : Celsion Corp Says Has Completed Enrollment Of Second Cohort Of Ovation Study And Expects To Report Clinical Data From That Cohort Mid Year . Celsion Corp says also expects to report translational data from first two cohorts of ovation study early in Q3 of 2016 .Celsion announces presentation of ovation study clinical trial design at upcoming asco 2016 meeting.  Full Article

Celsion Corp Q1 loss per share $0.24
Monday, 16 May 2016 08:21am EDT 

Celsion Corp : Celsion corporation reports first quarter 2016 financial results and provides business update . Q1 loss per share $0.24 .Q1 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Celsion Corp announces stock consolidation

* Is effecting a 1 for 14 reverse stock split of its common stock